Wall Street analysts expect that Insys Therapeutics, Inc. (NASDAQ:INSY) will announce sales of $35.29 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Insys Therapeutics’ earnings. The lowest sales estimate is $32.94 million and the highest is $40.00 million. Insys Therapeutics reported sales of $55.18 million during the same quarter last year, which would suggest a negative year over year growth rate of 36%. The business is scheduled to report its next earnings report on Thursday, November 2nd.

On average, analysts expect that Insys Therapeutics will report full year sales of $35.29 million for the current fiscal year, with estimates ranging from $147.97 million to $167.00 million. For the next financial year, analysts forecast that the firm will report sales of $181.12 million per share, with estimates ranging from $173.22 million to $186.13 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Insys Therapeutics.

Insys Therapeutics (NASDAQ:INSY) last released its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.12. Insys Therapeutics had a negative net margin of 9.63% and a negative return on equity of 3.02%. The business had revenue of $42.60 million during the quarter, compared to analyst estimates of $36.90 million. During the same period in the previous year, the business earned $0.13 EPS. Insys Therapeutics’s revenue was down 38.4% compared to the same quarter last year.

Several research firms have recently commented on INSY. BidaskClub raised shares of Insys Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 26th. TheStreet downgraded shares of Insys Therapeutics from a “c-” rating to a “d+” rating in a report on Monday, August 21st. Zacks Investment Research downgraded shares of Insys Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 9th. Royal Bank Of Canada cut their target price on shares of Insys Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Friday, August 4th. Finally, Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Insys Therapeutics in a research report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. Insys Therapeutics presently has an average rating of “Hold” and a consensus target price of $13.25.

In other news, major shareholder John N. Kapoor Trust Dated Sept acquired 17,500 shares of Insys Therapeutics stock in a transaction dated Friday, August 11th. The stock was purchased at an average cost of $8.93 per share, with a total value of $156,275.00. Following the completion of the purchase, the insider now directly owns 31,982 shares in the company, valued at approximately $285,599.26. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Saeed Motahari acquired 5,500 shares of Insys Therapeutics stock in a transaction dated Thursday, August 10th. The stock was purchased at an average cost of $8.92 per share, with a total value of $49,060.00. Following the completion of the purchase, the chief executive officer now owns 15,400 shares of the company’s stock, valued at $137,368. The disclosure for this purchase can be found here. Corporate insiders own 67.90% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC bought a new position in Insys Therapeutics in the 2nd quarter worth $138,000. Voya Investment Management LLC purchased a new stake in Insys Therapeutics in the 2nd quarter worth $149,000. BNP Paribas Arbitrage SA increased its stake in Insys Therapeutics by 213.2% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 13,133 shares of the specialty pharmaceutical company’s stock worth $166,000 after buying an additional 8,940 shares in the last quarter. Royal Bank of Canada increased its stake in Insys Therapeutics by 100.9% in the 2nd quarter. Royal Bank of Canada now owns 13,695 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 6,877 shares in the last quarter. Finally, American International Group Inc. increased its stake in Insys Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company’s stock worth $152,000 after buying an additional 953 shares in the last quarter. Institutional investors own 25.45% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Expect Insys Therapeutics, Inc. (INSY) Will Announce Quarterly Sales of $35.29 Million” was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/04/zacks-analysts-expect-insys-therapeutics-inc-insy-will-announce-quarterly-sales-of-35-29-million.html.

Shares of Insys Therapeutics (NASDAQ INSY) opened at 9.572 on Wednesday. The firm’s 50-day moving average is $9.24 and its 200-day moving average is $11.02. The company’s market cap is $695.85 million. Insys Therapeutics has a one year low of $8.68 and a one year high of $15.06.

About Insys Therapeutics

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Get a free copy of the Zacks research report on Insys Therapeutics (INSY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.